-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Polypeptide drugs are special drugs between small molecules and protein drugs.
They have the characteristics of high activity, high safety, strong specificity, certainty and good druggability.
They are used in the fields of diabetes, tumor, cardiovascular and other diseases.
Broad
.
Due to the difficulty and high barriers to the development of peptide drugs, multinational pharmaceutical companies such as Eli Lilly, Novo Nordisk, Novartis, and Takeda have made the development of peptide drugs in the international market surging by virtue of their capital and technological advantages
.
The Chinese market started late, but it is growing rapidly, and the market size is constantly expanding.
In 2019, it has reached more than 80 billion yuan.
With the continuous improvement of the domestic production rate of peptide drugs, the industry generally believes that there is a huge space for domestic replacement of imports in the future
.
At present, Chinese pharmaceutical companies mainly focus on imitation in the field of peptide drugs.
Since 2016, bivalirudin, ganirelix, cetrorelix, enfuvirtide, carbetocin and other varieties have been realized successively.
localization
.
In 2019, Shuangcheng Pharmaceutical's bivalirudin for injection was approved by the US FDA as a generic drug, opening the door to the US market
.
In recent years, the research and development of domestic peptide drugs has been hot, and many local pharmaceutical companies have not only stayed in the field of generic drugs, but have continued to make breakthroughs and in-depth layouts
.
Recently, many companies that are deploying peptide drugs have reported news of new harvests and new actions
.
For example, recently, Pulai Pharmaceutical announced that its original innovative drug antibacterial peptide PL-5 (Peceleganan) spray clinical trial application has been approved by the US FDA, and will directly conduct clinical phase II trials in the United States
.
If it goes well, it means that the product will successfully open the US market
.
It is reported that the antimicrobial peptide PL-5 can well solve the problem of bacterial resistance to antibiotics
.
Experiments show that PL-5 has strong bactericidal advantages against Gram-positive bacteria, Gram-negative bacteria and bacteria resistant to various antibiotics
.
The indication of this product is secondary wound infection, and it is intended to be used for burns, abrasions, cuts, lacerations, suture wounds, traumatic ulcers, bedsores, venous ulcer infections and Wagner grade II diabetic foot ulcers, etc.
wound infection
.
At present, PL-5 is also conducting Phase III clinical trials in China.
It is planned to complete all clinical trials and data statistics by the end of this year, and follow-up new drug marketing applications will be quickly introduced to the domestic market
.
On April 5th, the company focused on the research and development and commercialization of new-generation tumor immunotherapy innovative drugs announced that the company's drug candidate, the global first-in-class peptide tumor vaccine 3D189, has been issued by the National Medical Products Administration of China (NMPA).
The Drug Clinical Trial Approval Notice for the Phase I clinical study to evaluate the safety and immunogenicity of the drug in patients with hematological malignancies
.
At the end of March, Hanyu Pharmaceutical announced that the company had recently learned through the Brazilian Health Supervision Agency (ANVISA) that VOL Pharma, the company's agent and seller of terlipressin preparations for injection, had obtained the Brazilian marketing approval for the product
.
It is good news for the company that the new product has obtained the qualification for marketing authorization in Brazil
.
For another example, on April 15, Hanyu Pharmaceutical announced that the company signed the "Joint Research Center Agreement" with Shenzhen Advanced Institute and Shenzhen University of Technology to formally establish a joint research center for synthetic biology and peptide drugs
.
The two parties mainly cooperate on the research of anti-infection, anti-tumor, internal secretion, analgesic and other polypeptide drugs, and jointly develop new peptide drugs with good drugability and efficacy
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
They have the characteristics of high activity, high safety, strong specificity, certainty and good druggability.
They are used in the fields of diabetes, tumor, cardiovascular and other diseases.
Broad
.
Due to the difficulty and high barriers to the development of peptide drugs, multinational pharmaceutical companies such as Eli Lilly, Novo Nordisk, Novartis, and Takeda have made the development of peptide drugs in the international market surging by virtue of their capital and technological advantages
.
The Chinese market started late, but it is growing rapidly, and the market size is constantly expanding.
In 2019, it has reached more than 80 billion yuan.
With the continuous improvement of the domestic production rate of peptide drugs, the industry generally believes that there is a huge space for domestic replacement of imports in the future
.
At present, Chinese pharmaceutical companies mainly focus on imitation in the field of peptide drugs.
Since 2016, bivalirudin, ganirelix, cetrorelix, enfuvirtide, carbetocin and other varieties have been realized successively.
localization
.
In 2019, Shuangcheng Pharmaceutical's bivalirudin for injection was approved by the US FDA as a generic drug, opening the door to the US market
.
In recent years, the research and development of domestic peptide drugs has been hot, and many local pharmaceutical companies have not only stayed in the field of generic drugs, but have continued to make breakthroughs and in-depth layouts
.
Recently, many companies that are deploying peptide drugs have reported news of new harvests and new actions
.
For example, recently, Pulai Pharmaceutical announced that its original innovative drug antibacterial peptide PL-5 (Peceleganan) spray clinical trial application has been approved by the US FDA, and will directly conduct clinical phase II trials in the United States
.
If it goes well, it means that the product will successfully open the US market
.
It is reported that the antimicrobial peptide PL-5 can well solve the problem of bacterial resistance to antibiotics
.
Experiments show that PL-5 has strong bactericidal advantages against Gram-positive bacteria, Gram-negative bacteria and bacteria resistant to various antibiotics
.
The indication of this product is secondary wound infection, and it is intended to be used for burns, abrasions, cuts, lacerations, suture wounds, traumatic ulcers, bedsores, venous ulcer infections and Wagner grade II diabetic foot ulcers, etc.
wound infection
.
At present, PL-5 is also conducting Phase III clinical trials in China.
It is planned to complete all clinical trials and data statistics by the end of this year, and follow-up new drug marketing applications will be quickly introduced to the domestic market
.
On April 5th, the company focused on the research and development and commercialization of new-generation tumor immunotherapy innovative drugs announced that the company's drug candidate, the global first-in-class peptide tumor vaccine 3D189, has been issued by the National Medical Products Administration of China (NMPA).
The Drug Clinical Trial Approval Notice for the Phase I clinical study to evaluate the safety and immunogenicity of the drug in patients with hematological malignancies
.
At the end of March, Hanyu Pharmaceutical announced that the company had recently learned through the Brazilian Health Supervision Agency (ANVISA) that VOL Pharma, the company's agent and seller of terlipressin preparations for injection, had obtained the Brazilian marketing approval for the product
.
It is good news for the company that the new product has obtained the qualification for marketing authorization in Brazil
.
For another example, on April 15, Hanyu Pharmaceutical announced that the company signed the "Joint Research Center Agreement" with Shenzhen Advanced Institute and Shenzhen University of Technology to formally establish a joint research center for synthetic biology and peptide drugs
.
The two parties mainly cooperate on the research of anti-infection, anti-tumor, internal secretion, analgesic and other polypeptide drugs, and jointly develop new peptide drugs with good drugability and efficacy
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
